Rhinitis, Allergic
Recent clinical, regulatory, research and industry developments relating to this disease.
The airway neuro-immune axis as a therapeutic target in allergic airway diseases.
International consensus statement on allergy and rhinology: rhinosinusitis 2021.
Approval: Desloratadine Actavis (EMA)
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q4 2026.
Clinical MilestonesViewHide
- 2026-07-13ClinicalA Randomized, Double-blind, Placebo-controlled, Single-center Clinical Trial of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic RhinitisResults expected Q4 2026
- 2026-04-29ClinicalA Randomised, Double-blind, Placebo-controlled Exploratory Study to Explore the Efficacy and Safety of PQ Grass 27600 SU in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen ExposureResults posted
- 2026-01-01ClinicalA Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter CT to Evaluate Efficacy and Safety of Subcutaneous Immunotherapy in Subjects With Rhinitis With/Without Mild to Moderate Asthma Sensitized to Olive and Grass PollenPrimary completion
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Treatment of allergic rhinitis and urticaria. (2012)
Approval — Adults, adolescents (12 years and over) and children (6-11 years). Avamys is indicated fo… (2008)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Rhinitis, Allergic4
- Asthma3
- Air Pollutants1
- Air Pollution1
- Air Pollution, Indoor1
- Multimorbidity1
- Neuropeptides1
- Respiration Disorders1
Leading journals5
- Allergy1
- International forum of allergy & rhinology1
- Nature reviews. Disease primers1
- Respiratory research1
- The Journal of allergy and clinical immunology1
Leading researchers8
- Bachert C3
- Anto JM2
- Bosnic-Anticevich S2
- Bousquet J2
- Fokkens WJ2
- Mullol J2
- Naclerio R2
- Tomazic PV2
Affiliations (unnormalised)6
- Karolinska University Hospital2
- Medical University of Graz2
- Personalized Medicine Clinic Asthma & Allergy2
- Skin and Allergy Hospital2
- University of Amsterdam2
- Upper Airways Research Laboratory2
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Allergic rhinitis is an inflammation of the nasal mucosa triggered by allergens. It is a common chronic allergic condition and often occurs alongside other allergic diseases such as asthma and conjunctivitis.
It is caused by immunoglobulin E (IgE)-mediated reactions to inhaled allergens. The literature also identifies inhalant and occupational allergens as causes, with genetic factors contributing to susceptibility.
Exposure to allergens triggers IgE-mediated immune activation in the nasal mucosa, leading to allergic inflammation. The literature also describes a neuro-immune component in which allergens activate interactions between neurons and immune cells, with neurotransmitters, neuropeptides, histamine, and cytokines amplifying inflammation.
Risk factors include exposure to inhalant allergens, occupational allergens, indoor allergens such as house dust mites, pets, and molds, and tobacco smoke. Air pollution and climate change are also associated with onset or worsening of allergic rhinitis, and genetic factors increase susceptibility.
Treatment is described at the level of pharmacologic therapy and integrated care pathways. The grounding supports use of common drug-based management for allergic rhinitis, but does not specify individual drug classes in the supplied text; it also notes diagnosis-guided management and shared decision making within guideline-based care.
AI-generated summary grounded in MeSH and 5 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
An inflammation of the NASAL MUCOSA triggered by ALLERGENS.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.